Leukemia Drug Repurposed as Adipose-Targeted Senolytic to Reverse Metabolic Aging

#1

The accumulation of senescent cells in white adipose tissue (WAT) actively drives systemic metabolic dysfunction, insulin resistance, and pathological tissue fibrosis. Eliminating these cells via senolytics is a promising strategy for healthspan extension. A sweeping drug-repositioning screen of 2,150 clinical compounds has identified homoharringtonine (HHT)—an FDA-approved alkaloid currently utilized for chronic myeloid leukemia—as a highly potent senolytic.

Unlike traditional senolytics that universally target Bcl-2 or related anti-apoptotic pathways, HHT acts via direct physical interaction with Heat Shock Protein Family A Member 5 (HSPA5). HSPA5 is a molecular chaperone that becomes pathologically upregulated on the surface of senescent adipocytes to manage endoplasmic reticulum stress. By binding to the ATP-binding site of HSPA5 and neutralizing its ATPase activity, HHT selectively triggers caspase-3-mediated apoptosis in senescent cells while sparing non-senescent cells.

The systemic effects are profound. In high-fat (HF) diet-induced obese mice, HHT administration mitigates adipocyte hypertrophy, reduces white adipose tissue inflammation (clearing crown-like macrophage structures), and restores adipocyte precursor cell (APC) plasticity, facilitating healthy hyperplastic expansion and cold-induced thermogenesis. This remodeling yields robust improvements in whole-body glucose turnover and insulin sensitivity, alongside reduced hepatic steatosis.

In multiple aging models, including naturally aged cohorts and Zmpste24-/- progeroid mice, HHT improved physical parameters such as grip strength, reduced pulmonary and renal fibrosis, and extended overall lifespan. Notably, the drug achieved these geroprotective effects without suppressing hematopoiesis or inducing systemic toxicity, common limitations of HHT in oncological settings. Ex vivo testing on human subcutaneous adipose tissue confirmed the translatability of these senotherapeutic effects, significantly reducing senescence markers and SASP.

Source:

2 Likes
#2

Study Design Specifications

  • Type: In vitro (Human primary cell lines: HDFs, HUVECs, HPAs), In vivo (Murine models), Ex vivo (Human subcutaneous fat explants).
  • Subjects: * Wild-type C57BL/6N and C57BL/6J mice (Male, used in diet and natural aging models). N=4 to 10 per group depending on the assay.
    • p16-Luc transgenic mice (for in vivo senescence luminescence tracking).
    • Zmpste24-/- progeroid mice (Male and Female). N=4 to 9 per group.

Lifespan Analysis

When assessing murine lifespan data, it is imperative to evaluate control group longevity. According to a critical geroscience benchmark analysis, murine longevity interventions can only be considered with high confidence if the control lifespans approach ~900 days.

  • In the HF+Aging model utilized here, the control median lifespan was just 509 days.
  • Therefore, the lifespan extensions observed are likely rescuing premature metabolic-induced mortality rather than pushing the absolute biological limits of the organism. [Confidence: High]

Lifespan Data

  • High-Fat Diet + Aging Model: Median lifespan increased from 509 days (Control) to 551 days (HHT), representing an 8.2% extension. Maximum lifespan could not be determined as mice were sacrificed at 558 days for tissue harvesting.
  • Zmpste24-/- Progeroid Model: Median lifespan increased from 14 weeks to 15 weeks (7.1% extension). Maximum lifespan extended from 15 weeks to 19 weeks (26.6% extension).

Mechanistic Deep Dive

  • Target Pathway: Unlike Dasatinib + Quercetin or Navitoclax (which target anti-apoptotic Bcl-2 networks), HHT operates as an HSPA5 inhibitor. HSPA5 acts as an ER stress response chaperone. Senescent cells are heavily reliant on HSPA5 proteostasis to survive their immense secretory burden (SASP).
  • Apoptosis Trigger: HHT binding competitively inhibits HSPA5 ATPase activity, leading to unresolved ER stress and the rapid cleavage of procaspase-3 into active Caspase-3, triggering targeted apoptosis.
  • Organ-Specific Priorities: Adipose tissue is the primary responder. HHT selectively purges senescent adipocytes and senescent APCs. This shifts the WAT environment from a fibrotic, hypertrophic state to a hyperplastic, insulin-sensitive state, heavily restoring the transcription of healthy adipokines (e.g., Adiponectin, Adipsin).

Novelty

This study maps a completely novel senolytic mechanism (HSPA5 inhibition) using a compound with known human pharmacokinetics. It specifically highlights the vulnerability of metabolic tissues to ER-stress chaperone inhibition, offering a targeted approach to resolving visceral fat senescence over a systemic anti-apoptotic approach.

Related Reading:

https://medicalxpress.com/news/2026-04-dose-leukemia-drug-senescent-fat.html

Dosing

The supplementary materials explicitly detail the in vivo murine dosing parameters for the study.

Identified Dosing Information:

  • According to Supplementary Table 2, which outlines the administration dosages for high-fat diet-fed obese mice, the exact injection dose utilized for HHT (Compound 34) is 0.545 mg/kg.

Human Equivalent Dose (HED) Calculation: To extrapolate this murine dose to a human context, the standard FDA body surface area (BSA) normalization formula is applied.

  • Standard Formula: HED = Animal Dose (mg/kg) × (Mouse Km​ / Human Km​)
  • Km​ Constants: The accepted Km​ for a mouse is 3, and the Km​ for a standard human adult is 37.
  • Calculation: 0.545 mg/kg × (3 / 37) = 0.0442 mg/kg.

Absolute Dosing for a Standard Adult:

  • For a 70 kg human, the calculated absolute theoretical dose is 3.09 mg per administration.
  • For a 60 kg human, the theoretical dose is 2.65 mg per administration.

Translational Safety Analysis: Access to this specific empirical data confirms the severe translational toxicity risks. The FDA-approved induction dosage for Synribo (omacetaxine/HHT) in the treatment of chronic myeloid leukemia is 1.25 mg/m2 administered subcutaneously twice daily. For a standard adult, this chemotherapeutic dose equates to approximately 4.5 mg per day.

A proposed senolytic dose of ~3.1 mg sits squarely within the established oncological toxicity window. Therefore, there is no viable safety margin or distinct therapeutic index for the prophylactic deployment of HHT as a longevity intervention. Administration at this calculated HED would reliably induce the severe bone marrow suppression, anemia, and thrombocytopenia characteristic of the drug’s established human safety profile.

#3

How often is this dosed? The study says once a week:

“we treated 16-month-old mice with HHT once per week over a period of 12 months (Fig. 9A). We found that HHT significantly extended the lifespan and increased physical activity of aged mice”

Does this also slow down accumulation of non-senescent visceral fat? This excerpts from the study implies it does:

“We found that the #34 compound (HHT) mitigated weight gain and improved glucose regulation compared to PBS control in the absence of food intake differences”

“Importantly, we found a significant reduction in the fat weight in HHT-treated mice without significant effects on other organs (Fig. 2C and S6A), suggesting that reduced adiposity is the main contributor to body weight reduction. However, this effect was not observed in young mice fed a standard chow diet (Fig. S6B). Fasting plasma glucose levels were reduced by HHT (Fig. 2D) without a significant difference in fasting plasma insulin levels between the groups (Fig. 2E). Additionally, HOMA-IR was significantly lower in the HHT-treated mice than in PBS-treated mice with similar HOMA-%β level in both groups, suggesting that HHT improves HF-induced insulin resistance”

HHT increases energy expenditure which is partially how it reduces fat:

" To test whether HHT impacts thermogenesis, we examined the energy expenditure of the HHT-treated mice (Figs. S7A–C). We found that HHT treatment marginally (p = 0.056) increases the energy expenditure (Fig. S7C) and reduces the size of lipid droplets in brown adipose tissue (BAT) with significantly increased uncoupling protein (UCP1) expression in BAT (Figs. S7D and S7E). These data suggest that a moderate increase in energy expenditure by activation of BAT partially contributes to metabolic improvement by HHT treatment."

Improved liver health:

“we examined liver tissues and found significantly reduced steatosis in the HHT-treated liver with decreased TG accumulation and alanine aminotransferase (ALT) enzyme”

Improved bone and muscle health:

“HHT also increased bone mineral content, bone area, lean body mass (Figs. 8B, C, and S13A), and grip strength (Fig. 8D) in Zmpste24 -/- mice.”

Unknown what this means for skin, cardiovasular and organ health but collagen can be involved in fibrosis so this might be a good thing temporarily:

“Histological analysis revealed that HHT treatment decreases collagen deposition”

I’ve heard from Aubrey de Grey that there are things that increase mouse lifespan but that is more because they suppress cancer than anything else and it doesn’t translate to humans or other species as well. I wonder if this is another one of those. The study implies this was not the case:

“Mice often develop lymphoma, which is among the leading causes of death in aged mice60,61. As HHT has been used for the treatment of hematological oncology, the extended lifespan may primarily be due to the anti-cancer effects of HHT rather than its senotherapeutic effects. However, we did not find any differences in blood smear (Fig. S13B), CBC profiles (Supplementary Table 5), the numbers of Peyer’s patches (Fig. S13C), and the weight of inguinal lymph nodes (Fig. S13D) among Zmpste24 +/+, Zmpste24 +/-, and Zmpste24 -/- mice treated with HHT or vehicle (PBS) control. Additionally, no significant histological alterations were observed in the Peyer’s patches, inguinal lymph nodes, or the spleen (Fig. S13E). These results suggest that HHT mitigates aging phenotypes and extends lifespan in the absence of tissue toxicity in progeroid mice, independent of lymphocyte suppression.”

Generally good effects from HHT:

“We found that HHT significantly extended the lifespan and increased physical activity of aged mice (Fig. 9B and Supplementary Movie 2). This was accompanied by improved kidney function, represented by reduced proteinuria (Fig. 9C, D). It also improved skeletal muscle function measured by grip strength (Fig. 9E). In addition, HHT reduced fibrosis of the kidney, lung and liver in aged mice (Fig. S14A). HHT is primarily metabolized by the liver and excreted in the urine through the kidneys62,63. Thus, to test the potential adverse effects of prolonged treatment with HHT on these organs, we measured the levels of liver enzymes (i.e., aspartate aminotransferase (AST) and ALT), creatinine, and urea nitrogen (UN). We did not find any differences between PBS- and HHT-treated groups (Figs. S14B-G). Furthermore, as suppression of hematopoiesis is observed in HHT-treated cancer patients63,64, we examined the number of circulating hematopoietic cells and spleen histology, and again found no difference between control and long-term HHT-treated mice (Fig. S14H and Supplementary Table 6). Collectively, our data demonstrate that HHT delays aging and extends lifespan in mice without major adverse effects.”

Side effects listed on Wikipedia for this drug when used in humans, though the dosage frequency and amount would likely be different than what these mice were receiving:

image
image1475×1281 111 KB